Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

Next-Generation Gas Chromatograph and GC/MSD Enable New Levels of Performance

By BiotechDaily International staff writers
Posted on 12 Feb 2013
Image: The new Agilent 5977A Series GC/MSD, including the new 7890B GC (adjacent at right) (Photo courtesy of Agilent).
Image: The new Agilent 5977A Series GC/MSD, including the new 7890B GC (adjacent at right) (Photo courtesy of Agilent).
A new gas chromatograph (GC) and a mass selective detector to function with the GC offer a broad, feature-rich portfolio, and enable superior levels of sensitivity, reliability, and productivity.

Agilent Technologies (Santa Clara, CA, USA) introduces the Agilent 7890B gas chromatograph and the 5977A Series GC/MSD (mass selective detector) to offer the industry's broadest, feature-rich portfolio of superior performance GC, GC/MSD, and related software. Agilent also offers factory-tested, preconfigured solutions to help fast-track setup and operation. "Customers will find significant product improvements, eco-friendly capabilities, and lower cost of ownership, along with unsurpassed performance,” said Monty Benefiel, Agilent vice president for Gas Phase Systems.

Based on the known reliability of the Agilent GC platform, the new 7890B GC is faster, easier to operate, and more cost-effective. The 7890B GC features Improved performance specifications with advances in numerous detector modules; Lower operating costs and ecofriendly operation with power/gas management and sleep/wake modes; Seamless ordering of consumables and parts with an interactive graphical Parts Finder tool and consumables database; Easier, faster method development with integrated GC calculators and wizards; Better asset and resource management with integrated maintenance tools; Improved recovery of active compounds with Agilent's exclusive end-to-end Inert Flow Path deactivation technology; Reduced downtime for MS maintenance using the new Fast Vent feature.

The Agilent 7890B GC runs on Agilent OpenLAB Chromatography Data System software. The new Agilent OpenLAB CDS is up to 40 times faster than previous versions, with a new Data Analysis package and Intelligent Reporting. Advanced interactive integration tools and graphical displays accelerate data review, reducing time-to-results and freeing up operators for other tasks. "Our customers require the means to efficiently and accurately analyze their data as well as information about their laboratory assets to support decision making or gain further scientific insight. OpenLAB does all of that," said Bruce von Herrmann, Agilent vice president for Software and Informatics. "With streamlined workflows and complete data and method migration from ChemStation and EZChrom, OpenLAB is a fully scalable solution for a single laboratory, multiple workgroups, and entire enterprises."

The Agilent 5977A Series GC/MSD provides all the benefits of the 7890B GC plus features a redesigned inert MS ion source that enhances performance with highly efficient ion collection. The 5977A Series GC/MSD now offers the highest sensitivity on the market, with a new specification metric, the Instrument Detection Limit, for system-level performance in practice. Using Agilent's TwisTorr 304 FS turbomolecular vacuum pump, optimized for light gas operation, the new 5977A GC/MSD system is efficient and rugged, and has been evaluated and certified to meet Agilent’s leading quality standards. The GC/MSD runs on Agilent MassHunter Workstation software solution for high-throughput MS data analysis, and also includes a full version of MSD ChemStation to ensure compatibility with previously purchased instruments.

Related Links:
Agilent Technologies, Inc.
Agilent 7890B GC and 5977A Series GC/MSD
Agilent Inert Flow Path Solutions



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.